Survival database analysis of 1656 ovarian cancer patients identified those with high leptin (n = 108) and low leptin (n = 112) and showed that median leptin expression is associated with poorer prognosis in patients previously treated with platinum and paclitaxel/docetaxel [49]. This evidence concerns the gene LEP and ovarian cancer.